• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
ARNA (Arena Pharmaceuticals Inc.)
Last Trade 53.41 Dividend/Share 0 PE Ratio -18.11
Date May 24-2019 Dividend Yield 0.000 Return on Assets 61.79
Change 0.21 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.66 Price/Sale 3.254
Ask 0 LatestEPS Date 2018-12-31 Price to Book 2.12
Volume 40385 EPS ttm -2.950 Institutional % null
Avg Volume 0.6M Shares Outstanding 49.57M Insider % null
Open 53.2 Float 46.98M Short Ratio null
Prev Close 53.2 Return On Equity 68.14 5 Year Change % -0.154
High 53.835 Consensus EPS -0.81 2 Year Change % 2.870
Low 52.79 No. of Estimate 2.000 1 Year Change % 0.162
52 Week High 58 EPS Surprise $ null YTD Change % 0.328
52 Week Low 31.9699 EPS Surprise Percent 0 6 Month Change % 0.304
52 Week Change 14.655 EBITDA 0M 3 Month Change % 0.056
50 Day MA 48.039 Revenue 0M 1 Month Change % 0.163
200 Day MA Gross Profit 0M 5 Day Change % -0.002
Market Cap 2637.13M Cash 0M 30 Day Change % 0.126
Beta 1.581958 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin that has completed Phase III clinical trials for the treatment of weight management; APD791, an anti-thrombotic drug candidate, which completed Phase Ia and Phase Ib clinical trials; APD597 that is in Phase I clinical trials for the treatment of type II diabetes; APD916, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. The company?s drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including Constitutively Activated Receptor Technology and Melanophore Technology. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type II diabetes and other disorders; and Merck & Co., Inc. to develop therapeutics for atherosclerosis and other disorders. Arena Pharmaceuticals also has a strategic cooperation agreement with Siegfried Ltd to manufacture lorcaserin. The company was founded in 1997 and is based in San Diego, California.